Search Results - "BOGHAERT, Erwin"

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis by Jin, Sha, Cojocari, Dan, Purkal, Julie J, Popovic, Relja, Talaty, Nari N, Xiao, Yu, Solomon, Larry R, Boghaert, Erwin R, Leverson, Joel D, Phillips, Darren C

“…Patients with acute myeloid leukemia (AML) frequently do not respond to conventional therapies. Leukemic cell survival and treatment resistance have been…”
Get full text

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models by Punnoose, Elizabeth A, Leverson, Joel D, Peale, Franklin, Boghaert, Erwin R, Belmont, Lisa D, Tan, Nguyen, Young, Amy, Mitten, Michael, Ingalla, Ellen, Darbonne, Walter C, Oleksijew, Anatol, Tapang, Paul, Yue, Peng, Oeh, Jason, Lee, Leslie, Maiga, Sophie, Fairbrother, Wayne J, Amiot, Martine, Souers, Andrew J, Sampath, Deepak

“…BCL-2 family proteins dictate survival of human multiple myeloma cells, making them attractive drug targets. Indeed, multiple myeloma cells are sensitive to…”
Get full text

Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates by Boghaert, Erwin R, Cox, Megan C, Vaidya, Kedar S

“…Antibody-drug conjugates (ADC) have emerged as one of the pillars of clinical disease management in oncology. The biggest hurdle to widespread development and…”
Get full text

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope by Phillips, Andrew C, Boghaert, Erwin R, Vaidya, Kedar S, Mitten, Michael J, Norvell, Suzanne, Falls, Hugh D, DeVries, Peter J, Cheng, Dong, Meulbroek, Jonathan A, Buchanan, Fritz G, McKay, Laura M, Goodwin, Neal C, Reilly, Edward B

“…Targeting tumor-overexpressed EGFR with an antibody-drug conjugate (ADC) is an attractive therapeutic strategy; however, normal tissue expression represents a…”
Get full text

ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET -Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence by Wang, Jieyi, Anderson, Mark G, Oleksijew, Anatol, Vaidya, Kedar S, Boghaert, Erwin R, Tucker, Lora, Zhang, Qian, Han, Edward K, Palma, Joann P, Naumovski, Louie, Reilly, Edward B

“…Despite the importance of the oncogene in many malignancies, clinical strategies targeting c-Met have benefitted only small subsets of patients with tumors…”
Get full text

Application of LDH assay for therapeutic efficacy evaluation of ex vivo tumor models by Cox, Megan C., Mendes, Rita, Silva, Fernanda, Mendes, Teresa F., Zelaya-Lazo, Adelyn, Halwachs, Kathleen, Purkal, Julie J., Isidro, Inês A., Félix, Ana, Boghaert, Erwin R., Brito, Catarina

“…The current standard preclinical oncology models are not able to fully recapitulate therapeutic targets and clinically relevant disease biology, evidenced by…”
Get full text

Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery by Stock, Kristin, Estrada, Marta F., Vidic, Suzana, Gjerde, Kjersti, Rudisch, Albin, Santo, Vítor E., Barbier, Michaël, Blom, Sami, Arundkar, Sharath C., Selvam, Irwin, Osswald, Annika, Stein, Yan, Gruenewald, Sylvia, Brito, Catarina, van Weerden, Wytske, Rotter, Varda, Boghaert, Erwin, Oren, Moshe, Sommergruber, Wolfgang, Chong, Yolanda, de Hoogt, Ronald, Graeser, Ralph

“…Two-dimensional (2D) cell cultures growing on plastic do not recapitulate the three dimensional (3D) architecture and complexity of human tumors. More…”
Get full text

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia by Cojocari, Dan, Smith, Brianna N, Purkal, Julie J, Arrate, Maria P, Huska, Jason D, Xiao, Yu, Gorska, Agnieszka, Hogdal, Leah J, Ramsey, Haley E, Boghaert, Erwin R, Phillips, Darren C, Savona, Michael R

“…Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2…”
Get full text

Tackling the tumor microenvironment - how can complex tumor models in vitro aid oncology drug development? by Cox, Megan C, Mendes, Rita, Halwachs, Kathleen N, Domenici, Giacomo, Brito, Catarina, Boghaert, Erwin R

“…Identifying effective cancer drugs remains an inefficient process. Drug efficacy in traditional preclinical cancer models translates poorly into therapy in the…”
Get more information

Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate by Anderson, Mark G., Falls, Hugh D., Mitten, Michael J., Oleksijew, Anatol, Vaidya, Kedar S., Boghaert, Erwin R., Gao, Wenqing, Palma, Joann P., Cao, Diana, Chia, Puey-Ling, John, Thomas, Gan, Hui K., Scott, Andrew M., Reilly, Edward B.

“…Abstract ABBV-321 (serclutamab talirine), a next-generation EGFR-targeted antibody–drug conjugate (ADC) incorporates a potent pyrrolobenzodiazepine (PBD) dimer…”
Get full text

Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read‐outs by Santo, Vítor E., Rebelo, Sofia P., Estrada, Marta F., Alves, Paula M., Boghaert, Erwin, Brito, Catarina

“…There is cumulating evidence that in vitro 3D tumor models with increased physiological relevance can improve the predictive value of pre‐clinical research and…”
Get full text

Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures by Abreu, Sofia, Silva, Fernanda, Mendes, Rita, Mendes, Teresa F., Teixeira, Marta, Santo, Vítor E., Boghaert, Erwin R., Félix, Ana, Brito, Catarina

“…Ovarian carcinoma (OvC) remains a major therapeutic challenge due to its propensity to develop resistance after an initial response to chemotherapy…”
Get full text

Discovery of a Potent and Selective BCL‑XL Inhibitor with in Vivo Activity by Tao, Zhi-Fu, Hasvold, Lisa, Wang, Le, Wang, Xilu, Petros, Andrew M, Park, Chang H, Boghaert, Erwin R, Catron, Nathaniel D, Chen, Jun, Colman, Peter M, Czabotar, Peter E, Deshayes, Kurt, Fairbrother, Wayne J, Flygare, John A, Hymowitz, Sarah G, Jin, Sha, Judge, Russell A, Koehler, Michael F. T, Kovar, Peter J, Lessene, Guillaume, Mitten, Michael J, Ndubaku, Chudi O, Nimmer, Paul, Purkey, Hans E, Oleksijew, Anatol, Phillips, Darren C, Sleebs, Brad E, Smith, Brian J, Smith, Morey L, Tahir, Stephen K, Watson, Keith G, Xiao, Yu, Xue, John, Zhang, Haichao, Zobel, Kerry, Rosenberg, Saul H, Tse, Chris, Leverson, Joel D, Elmore, Steven W, Souers, Andrew J

“…A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based…”
Get full text

The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors by Boghaert, Erwin R., Lu, Xin, Hessler, Paul E., McGonigal, Thomas P., Oleksijew, Anatol, Mitten, Michael J., Foster-Duke, Kelly, Hickson, Jonathan A., Santo, Vitor E., Brito, Catarina, Uziel, Tamar, Vaidya, Kedar S.

“…Improving the congruity of preclinical models with cancer as it is manifested in humans is a potential way to mitigate the high attrition rate of new cancer…”
Get full text

Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR by Vaidya, Kedar S., Mitten, Michael J., Zelaya-Lazo, Adelyn L., Oleksijew, Anatol, Alvey, Cory, Falls, Hugh D., Mishra, Sasmita, Palma, Joann, Ansell, Peter, Phillips, Andrew C., Reilly, Edward B., Anderson, Mark, Boghaert, Erwin R.

“…Purpose: Depatux-m is an antibody drug conjugate (ADC) that targets and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor…”
Get full text

Patient-derived explants of colorectal cancer: histopathological and molecular analysis of long-term cultures by da Mata, Sara, Franchi-Mendes, Teresa, Abreu, Sofia, Filipe, Bruno, Morgado, Sónia, Mesquita, Marta, Albuquerque, Cristina, Fonseca, Ricardo, Santo, Vítor E., Boghaert, Erwin R., Rosa, Isadora, Brito, Catarina

“…© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative…”
Get full text

Exploring Metabolic Signatures of Ex Vivo Tumor Tissue Cultures for Prediction of Chemosensitivity in Ovarian Cancer by Mendes, Rita, Graça, Gonçalo, Silva, Fernanda, Guerreiro, Ana C. L, Gomes-Alves, Patrícia, Serpa, Jacinta, Boghaert, Erwin R, Alves, Paula M, Félix, Ana, Brito, Catarina, Isidro, Inês A

“…Predicting patient response to treatment and the onset of chemoresistance are still major challenges in oncology. Chemoresistance is deeply influenced by the…”
Get full text

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets by Souers, Andrew J, Leverson, Joel D, Boghaert, Erwin R, Ackler, Scott L, Catron, Nathaniel D, Chen, Jun, Dayton, Brian D, Ding, Hong, Enschede, Sari H, Fairbrother, Wayne J, Huang, David C S, Hymowitz, Sarah G, Jin, Sha, Khaw, Seong Lin, Kovar, Peter J, Lam, Lloyd T, Lee, Jackie, Maecker, Heather L, Marsh, Kennan C, Mason, Kylie D, Mitten, Michael J, Nimmer, Paul M, Oleksijew, Anatol, Park, Chang H, Park, Cheol-Min, Phillips, Darren C, Roberts, Andrew W, Sampath, Deepak, Seymour, John F, Smith, Morey L, Sullivan, Gerard M, Tahir, Stephen K, Tse, Chris, Wendt, Michael D, Xiao, Yu, Xue, John C, Zhang, Haichao, Humerickhouse, Rod A, Rosenberg, Saul H, Elmore, Steven W

“…Inhibition of prosurvival proteins of the BCL family is a promising anticancer strategy; however, the similarities between the family members make the…”
Get full text

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy by Leverson, Joel D, Phillips, Darren C, Mitten, Michael J, Boghaert, Erwin R, Diaz, Dolores, Tahir, Stephen K, Belmont, Lisa D, Nimmer, Paul, Xiao, Yu, Ma, Xiaoju Max, Lowes, Kym N, Kovar, Peter, Chen, Jun, Jin, Sha, Smith, Morey, Xue, John, Zhang, Haichao, Oleksijew, Anatol, Magoc, Terrance J, Vaidya, Kedar S, Albert, Daniel H, Tarrant, Jacqueline M, La, Nghi, Wang, Le, Tao, Zhi-Fu, Wendt, Michael D, Sampath, Deepak, Rosenberg, Saul H, Tse, Chris, Huang, David C S, Fairbrother, Wayne J, Elmore, Steven W, Souers, Andrew J

“…The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia…”
Get more information

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells by DAMELIN, Marc, GELES, Kenneth G, BEHRENS, Carmen, CHOE, Sung E, RIOS, Carol, GRUZAS, Janet, SRIDHARAN, Latha, DOUGHER, Maureen, KUNZ, Arthur, HAMANN, Philip R, EVANS, Deborah, ARMELLINO, Douglas, FOLLETTIE, Maximillian T, KHANDKE, Kiran, MARQUETTE, Kimberly, TCHISTIAKOVA, Lioudmila, BOGHAERT, Erwin R, ABRAHAM, Robert T, WISTUBA, Ignacio I, ZHOU, Bin-Bing S, PING YUAN, BAXTER, Michelle, GOLAS, Jonathon, DIJOSEPH, John F, KARNOUB, Maha, SHUGUANG HUANG, DIESL, Veronica

“…Poorly differentiated tumors in non-small cell lung cancer (NSCLC) have been associated with shorter patient survival and shorter time to recurrence following…”
Get full text